Close

Brainstorm Cell Therapeutics (BCLI) Agrees with Massachusetts General Hospital & California Pacific Medical Center to Join in Phase 3 Trial of NurOwn in ALS

July 18, 2017 5:56 AM EDT Send to a Friend
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login